Zymeworks (ZYME) to Release Quarterly Earnings on Thursday

Zymeworks (NYSE:ZYME) is set to release its earnings data after the market closes on Thursday, May 2nd. Analysts expect Zymeworks to post earnings of ($0.31) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.19. The firm had revenue of $16.93 million during the quarter, compared to the consensus estimate of $18.32 million. Zymeworks had a negative net margin of 156.12% and a negative return on equity of 26.20%. On average, analysts expect Zymeworks to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zymeworks Trading Up 3.0 %

Shares of NYSE:ZYME opened at $8.58 on Wednesday. The company has a market cap of $605.49 million, a price-to-earnings ratio of -4.93 and a beta of 1.14. The company has a 50-day moving average price of $10.37 and a 200-day moving average price of $9.68. Zymeworks has a 12 month low of $6.01 and a 12 month high of $13.14.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.